Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H14F4N4O2S |
| Molecular Weight | 438.399 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
FC1=CC=C2N([C@H](C3CC3)C4=CNN=C4C2=C1)S(=O)(=O)C5=CC=C(N=C5)C(F)(F)F
InChI
InChIKey=LBJYPLZODCWHKE-GOSISDBHSA-N
InChI=1S/C19H14F4N4O2S/c20-11-3-5-15-13(7-11)17-14(9-25-26-17)18(10-1-2-10)27(15)30(28,29)12-4-6-16(24-8-12)19(21,22)23/h3-10,18H,1-2H2,(H,25,26)/t18-/m1/s1
| Molecular Formula | C19H14F4N4O2S |
| Molecular Weight | 438.399 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:36:23 GMT 2023
by
admin
on
Sat Dec 16 10:36:23 GMT 2023
|
| Record UNII |
VKU3JVL7UC
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
ELND-007
Created by
admin on Sat Dec 16 10:36:23 GMT 2023 , Edited by admin on Sat Dec 16 10:36:23 GMT 2023
|
PRIMARY | MedKoo CAT#: 206087;CAS#: 1444006-79-4;Description: ELND007 is a Gamma secretase inhibitor. (Last update: 8/21/2015).;Synonym: ELND007, ELND-007, ELND 007. | ||
|
1444006-79-4
Created by
admin on Sat Dec 16 10:36:23 GMT 2023 , Edited by admin on Sat Dec 16 10:36:23 GMT 2023
|
PRIMARY | |||
|
VKU3JVL7UC
Created by
admin on Sat Dec 16 10:36:23 GMT 2023 , Edited by admin on Sat Dec 16 10:36:23 GMT 2023
|
PRIMARY | |||
|
46912223
Created by
admin on Sat Dec 16 10:36:23 GMT 2023 , Edited by admin on Sat Dec 16 10:36:23 GMT 2023
|
PRIMARY | |||
|
300000042382
Created by
admin on Sat Dec 16 10:36:23 GMT 2023 , Edited by admin on Sat Dec 16 10:36:23 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Originator: Elan Pharmaceuticals; Class: Pyrazole, Small molecule, Sulfonamide; Mechanism of Action: Amyloid precursor protein secretase inhibitor; Highest Development Phase: Research for Alzheimer's disease; Most Recent Events: 03 Aug 2011 Early investigations for .BETA.-secretase inhibitors are ongoing - preclinical development for ELND 007 has been discontinued, 13 Apr 2007 Preclinical development is ongoing, 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into Pfizer
|
||
|
ACTIVE MOIETY |
Compounds 30 (ELND006) and 34 (ELND007) both entered human clinical trials. The in vitro and in vivo characteristics for these two compounds are described.
|
